title: [Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?]
authors: Unidad de Hipertensión, Instituto de Investigación I+12, Hospital 12 de Octubre, Madrid, España.
authors: G
authors: G
authors: Ruiz-Hurtado
authors: Hospital Universitario de Móstoles, Móstoles, Madrid, España.
authors: L
authors: L
authors: Vigil
authors: Unidad de Hipertensión, Instituto de Investigación I+12, Hospital 12 de Octubre, Madrid, España; Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España; Escuela de Estudios Posdoctorales e Investigación, School of Doctoral, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España. Electronic address: ruilope@icloud.com.
authors: L M
authors: LM
authors: Ruilope
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000091362:PCSK9 Inhibitors; D011379:Prognosis; D012307:Risk Factors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9